List view / Grid view
18 November 2013 | By Dr Kevin Robinson
The response to a lack of skilled managers is often to take a ‘sticking plaster’ approach to the problem by deciding to take on one or two pricing managers and have them report into the commercial or finance team. Experience to date shows that this will have limited success, for…
5 November 2013 | By Dr Kevin Robinson
Few markets have undergone the degree of change experienced by the life sciences sector in recent years. The end of the blockbuster drug era, the increasing cost of product development and a growing population putting greater strain on healthcare services around the world have combined at a time when economic…
28 October 2013 | By Dr Kevin Robinson
End-users, be they patients or consumers, are taking a good look at the cardiovascular benefits of omega-3s … and tend to like what they see.
Read the free digital version of Issue #5 2013 of European Pharmaceutical Review magazine...
In this PCR In-Depth Focus: Challenges for qRT-PCR in detecting / quantifying microRNA in vitro and in vivo; Emerging clinical applications of digital PCR; Workshop Preview: Advanced 3d cell based assays, preparation, analysis and troubleshooting...
In this Raman spectroscopy In-Depth Focus: Raw material identification using dual laser handheld Raman spectroscopy; Raman spectroscopy in support of biotherapeutic production: applications in protein formulation and purification; Raman Spectroscopy Roundtable...
25 October 2013 | By Dr Kevin Robinson
It doesn’t seem to matter what the industry is or, indeed, what the event is these days, the same question pops up at regular intervals: where’s the innovation? I’m happy to report that innovation is very much alive and well in the pharmaceutical industry and was on show to the…
25 October 2013 | By Dr Kevin Robinson
CPhI Worldwide 2013: eight halls, more than 30,000 attendees from 140 countries and 2200 exhibitors. The “world's leading pharmaceutical networking event,” colocated with ICSE, P-MEC and InnoPack, was back in Frankfurt, Germany, and my mission was to find a single coherent take-home message...
22 October 2013 | By David Elder, JPAG and GlaxoSmithKline / Andrew Teasdale, JPAG chairman and AstraZeneca
Historically, control over metal impurities has been achieved via pharmacopoeial heavy metals limit tests, e.g. United States Pharmacopeia (USP) .
22 October 2013 | By Birthe V. Nielsen, Faculty of Engineering and Science, University of Greenwich
Neuromodulators such as calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) act as biomarkers for pain assessment (pre-clinical). These markers can be detected at low concentrations by Electrospray Ionisation (ESI) Mass Spectrometry (MS). Currently, little is known about the factors affecting responsiveness in the ESI process though the response…
22 October 2013 | By Diana Russom (Department of Information Technology Systems, Beckman Research Institute of the City of Hope) / Amira Ahmed and Nancy Gonzalez (Laboratory for Cellular Medicine, Beckman Research Institute of the City of Hope) / David L. DiGiusto (Laboratory for Cellular Medicine and Department of Virology, Beckman Research Institute of the City of Hope)
The volume of data generated in modern medical research centres is growing exponentially and becoming more diverse as advancements in automation and biotechnology transform the basic operations of these laboratories and clinics. Patient care and laboratory instrumentation generate data at a rate that rapidly outpaces the ability to track and…
22 October 2013 | By Amancio Carnero, Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas
There is an urgent need to predict which treatment will report the most benefit to a patient with cancer. To that end, scientists are exploring any possible biomolecule in the organism that can mark each individual for its adequate treatment. If achieved, it will open a personalised medicine era.
22 October 2013 | By Mark Wade, Center for Genomic Science of IIT@SEMM
Protein-protein interactions (PPI) form the backbone of all cellular signalling networks, and aberrant PPI contribute to the pathology of several diseases. Thus, strategies to identify PPI modulators are expected to be therapeutically beneficial. However, there are very few examples of clinically approved PPI modulators, reflecting the difficulties of identifying effective…
22 October 2013 | By Michael J. Miller, President, Microbiology Consultants, LLC and Suzan Mohammed Ragheb, Department of Biotechnology, The Nile Company for Pharmaceuticals and Chemical Industries
Rapid microbiological methods (RMM) have gained popularity and acceptance within a number of industry sectors, including food and beverages, diagnostics, environmental, personal care and pharmaceuticals. In recent years, many firms have successfully validated and implemented RMMs for a wide variety of applications. However, many geographic areas around the world still…
Read the free digital version of the August / September edition of European Pharmaceutical Review magazine...
